The CD44 cell surface proteoglycan participates in a variety of CD44v6 has been also described in high-grade, but not in functions including lymphohematopoiesis, lymphocyte homing low-grade, non-Hodgkin's lymphomas. [25] [26][27] and tumor metastasis. In addition to the standard form Upon interaction with its natural ligand, or when ligated by with lymphoma (both Hodgkin's and non-Hodgkin's).
markers such as lactate dehydrogenase, ␤ 2 -microglobulin, thymidine kinase, CD23 and CD27 have been reported to correlate positively with clinical stage and prognosis. [42] [43] [44] [45] More Introduction recently, serum levels of the adhesion molecule ICAM-1 have been shown to reflect clinical stage and to provide a prognos-CD44 is an adhesion molecule of the proteoglycan family that tic marker for B-CLL. 46 We have reported previously that Bis expressed on the surface of virtually all hematopoietic CLL cells express surface CD44st at variable density, and that cells. 1 Several functions of the CD44 molecule, such as cellthis phenotypic feature allows distinction of two groups of to-extracellular matrix adhesion, lymphocyte homing, lympatients with significantly different survival rates. 47, 48 In this phohematopoiesis, T cell activation and tumor metastasis, study, we show that serum levels of CD44st, but not CD44v5 depend on the ability of CD44 to recognize the extracellular and v6, are elevated in a proportion of B-CLL patients, and matrix component, hyaluronic acid.
2-8 CD44 is also expressed that they correlate significantly with another soluble marker, on epithelial cells, fibroblasts, muscle cells, central nervous ␤ 2 -microglobulin. Serum CD44st exhibits a molecular weight system white matter, glial cells, and a wide variety of lower than that determined in B-CLL cell lysates, thus indicattumors. 9, 10 ing that it is indeed a shed molecular form. We finally show Besides the 'standard' form of 80-90 kDa (CD44st), several that high levels of serum CD44st associate significantly with 'variant' isoforms (CD44v) are generated by pre-mRNA altertumor burden and with a number of unfavorable prognostic native splicing of at least 10 exons.
11-13 These variants differ factors, and that consistent variations of CD44st serum levels from the standard form in that they contain additional peptide occur with disease progression and with therapy-related cytodomains inserted into the membrane-proximal extracellular reduction. portion of the molecule. Splice variants carrying sequences encoded by exon v6 are selectively expressed in metastatic animal cancer cell lines, and they confer metastatic behavior Materials and methods on non-metastatic tumor cells. 14, 15 In some cancers, eg colon, expression of CD44v (v5 and v6) is associated with tumor pro-bone marrow lymphocytosis Ͼ30%.
49 Diagnosis was confirmed by immunophenotypic analysis of surface Ig light and heavy chains, CD5 and HLA-DR expression. Residual T and 10 × 10 6 B-CLL cells were washed with PBS and lysed with RIPA buffer containing 1% Triton X100 and 0.15 m NaCl for NK cells were enumerated by immunofluorescence staining for CD3 and CD16, and flow cytometric analysis (FACScan; 1 h in the cold. Cell lysates were centrifuged for 1 h at 10 000 r.p.m. and supernatants were analyzed. As a control, we used Becton Dickinson, San José, CA, USA). Expression of CD44st and of its variant isoforms, v5 and v6, on B-CLL cells was cell lysates from the lung adenocarcinoma cell line A-549 (American Type Culture Collection, Rockville, MD, USA) also analyzed.
All of the moAbs used for immunophenotypic analyses because these cells express CD44st, but none of the heavier variant isoforms (our unpublished observations; see also were from Becton Dickinson, except anti-CD44st, v5 and v6 that were purchased from Immunotech (Marseille, France).
Results). Cell lysates and sera from normal subjects and from patients with B-CLL were precleared using protein AThe pattern of bone marrow infiltration, 39 was evaluated in bone marrow biopsies from 101 patients. Biopsy was not perSepharose (Pharmacia, Uppsala, Sweden), and immunoprecipitated with anti-CD44st antibodies. We used, with identical formed in the remaining 21 patients due to advanced age, cardiovascular risk factors or refusal of informed consent.
results, two anti-CD44 moAbs; one was from clone J173 (Immunotech) and the other was from clone 50B4, kindly proClinical evaluation of the patients included assessment of PB lymphocytosis, liver, spleen and lymph node enlargement, vided by Dr Michelle Letarte (University of Toronto, Canada). As a control moAb for immunoprecipitation we used an antilymphocyte doubling time (LDT), 37 and staging according to Binet et al.
35
CD4 moAb (Serotech, Oxford, UK). After several washings, immunoprecipitates were eluted by boiling in non-reducing At the time of study, 44/122 patients were receiving treatment. However, in all of these cases, the number of PB lymrunning buffer, and separated in 7.5% SDS-PAGE. Proteins were blotted onto nitrocellulose membranes (Amersham, phocytes was Ͼ5000/l. Of the 78 untreated patients, 17 required subsequent therapy because of progressive disease.
Arlington Heights, IL, USA). Membranes were saturated overnight with non-fat dry milk (Merck, Darmstadt, Germany) in Therapy with chlorambucil and prednisone was applied in B-CLL patients at stage C of disease and in patients at B stage PBS, and subsequently incubated with 10 g anti-CD44st moAb in PBS, supplemented with 1% non-fat dry milk, for 1 h showing progressive disease.
In 18 patients that were available for a follow-up study, sera under continuous stirring. After exhaustive rinsing with PBS containing 0.5% Tween 20, membranes were incubated with were obtained twice for CD44st determination in stable disease phase, during disease progression, or in regression due affinity-purified, peroxidase-conjugated rabbit anti-mouse Ig (Dako, Glostrup, Denmark). Protein bands were revealed to chemotherapy, in a time-period of 4-9 months. The two data points were compared in order to determine whether or using the ECL system (Amersham). Molecular weight markers were from Biorad (Richmond, VA, USA). not CD44st serum levels could represent a reliable indicator of disease course.
In additional experiments, we used moAbs to the variant isoforms v5 and v6 (Bender) as the primary reagents for immunoprecipitation, followed by anti-CD44st moAbs (clone J173) as the revealing reagent in immunoblotting. These experiments were aimed at assessing the molecular weight of CD44 Quantitative determination of serum CD44st, CD44v5 variant isoforms.
and CD44v6
Sera from 122 B-CLL patients and from 48 normal subjects Statistical analyses (age 40-65 years) were analyzed for detection and quantitation of CD44st, v5 and v6. Sera were centrifuged, dispensed
Variance analysis was used, considering CD44 as an independent variable and the other variables as factors into aliquots and kept at −80°C until used. Enzyme linked immuno sorbent assay (ELISA) kits were utilized (Bender Med (lymphocytosis, splenomegaly, Binet stage, therapy requirement, LDT and pattern of bone marrow infiltration). SignifiSystems, Vienna, Austria). Standard samples and sera were diluted and incubated in 96-well ELISA plates coated with cance was evaluated using the Fisher's F ratio and statistics. Probability (P) values Ͻ0.05 were considered as statistically moAbs specific for CD44st, v5 and v6. The same antibodies labelled with peroxidase were also added in the assay. After significant. The 'r' correlation coefficients between peripheral blood HLA-DR + B cell counts and CD44st serum levels, as rinsing, the TMB substrate was dispensed into the wells and the colorimetric reaction was measured using an ELISA reader.
well as between serum levels of CD44st and ␤ 2 -microglobulin, were evaluated using least squares regression equations. Data were expressed as ng/ml.
The relatively short period of this study (ෂ3 years) did not allow multivariate analyses due to the extremely low number of events (deaths), and to the consequent inability to construct curves of survival.
Quantitative determination of serum ␤ 2 -microglobulin Sera from 40 B-CLL patients, analyzed previously for CD44st Results were selected at random in order to cover the whole range of CD44st values, from normal to elevated. ␤ 2 -microglobulin
The major clinical and laboratory features of the 122 B-CLL cases are summarized in Table 1 . Over 75% of the patients concentrations were determined in these sera using a microsphere enzyme immuno assay (MEIA, Abbott Laborahad Ͼ80% PB-B lymphocytes enumerated as HLA-DR + or surface Ig + cells. In all of the cases, circulating B cells exceeded tories, Abbott Park, IL, USA). Data were expressed as mg/l. Table 1 Clinical and laboratory features of B-CLL patients at the counts Ͻ60 000/l were above the cut-off level of serum time of study CD44st. As shown in CD44st. A significant difference between mean values in the two groups was apparent (P Ͻ 0.0001).
A comparison of bone marrow diffuse vs non-diffuse pattern 60%, with the exception of seven patients whose PB-B cells of lymphocytic infiltration revealed that, among the 101 comprised between 40 and 60%. However, the absolute lympatients available for evaluation, 26 were in the first group phocyte count was always Ͼ5000/l. and 75 in the second. No significant differences between the two groups were detected as for the mean serum levels of CD44st (see Table 2 ), as well as for the number of patients
Quantitative determination of serum CD44st in B-CLL with elevated CD44st (42% of the patients with the diffuse pattern, and 45% with the non-diffuse pattern). In all of the B-CLL cases, 100% of the PB lymphocytes, thus Staging of B-CLL patients according to Binet et al, 35 indiincluding also residual T and NK cells, expressed surface cated that 68/121 cases were classifiable as stage A, whereas CD44st. Serum CD44st was determined using an ELISA assay.
53/121 cases were at stage B or C. When soluble CD44st levValues were compared with those of 48 age-matched normal els in the two groups were compared, 23/68 (34%) stage A subjects. Means of the latter values (477.9 ± 133.8 ng/ml) patients and 30/53 (57%) stage B + C patients were above the were increased by 2 s.d. to establish the cut-off threshold cut-off levels. There was a statistically significant difference (745 ng/ml).
between mean values in the two groups (P Ͻ 0.0013). In 54/122 cases, serum levels of CD44st were above the We also evaluated the relevance of serum CD44st levels by cut-off value and ranged from 778 to 6240 ng/ml. In 20/54 comparing the group of patients that required treatment with cases, CD44st serum levels were above 1000 ng/ml. those that did not need therapeutic intervention (61/122 and The relationship between serum CD44st levels and the 61/122 patients, respectively). Thirty-three out of 61 (54%) major clinical and biologial features of the B-CLL patients was patients that needed treatment had elevated serum CD44st, evaluated next (Table 2) . Twenty-seven out of 122 patients and only 21/61 (34%) patients not requiring therapy were had Ͼ60 000/l circulating lymphocytes. Among these 27 above the cut-off level. The difference of mean values patients, 18 (66%) showed soluble CD44st levels above the between the two groups was statistically significant cut-off value. Only 36/95 (38%) patients with lymphocyte (P Ͻ 0.023).
We finally asked if the number of PB leukemic B cells corre- Table 2 Relationship between serum CD44st levels (ng/ml) and lated with the amount of soluble CD44st. A highly significant certain clinical and laboratory features of B-CLL patients correlation coefficient was determined between the two parameters (r = 0.485, P = 0.0001), thus indicating that increase of Clinical and laboratory Serum CD44st Fisher's F P soluble CD44st parallels that of circulating HLA-DR + or sIg CLL cell clones, albeit at very low density (5-10% compared 2980 ng/ml). It should be reiterated here that this study has a preliminary significance only, and that a longer follow-up with the density of CD44st expression). Accordingly, soluble CD44v5 and v6 were detected in the serum of B-CLL patients observation of this chronic disorder is necessary. at levels comparable to those of normal subjects. Concentrations of v5 and v6 in sera from normal donors were 39 ± 20 ng/ml and 154 ± 55 ng/ml, respectively. The cut-off Molecular weight analysis of cell-bound and soluble CD44 values determined as the mean +2 s.d. were therefore 79 ng/ml and 264 ng/ml, for v5 and v6, respectively. In 2/122 and 4/122 B-CLL cases, serum CD44v5 and v6 were marThe molecular weight of CD44 was analyzed by immunoprecipitation and immunoblotting of B-CLL cell lysates, of a lung ginally elevated above the cut-off values. No relationship between serum CD44v5 and v6 and any of the investigated adenocarcinoma cell line, and of sera from both normal agematched subjects and from B-CLL patients. In Figure 2a we clinical and biological parameters of disease was therefore apparent.
show that similar patterns are observed when cell lysates and sera from B-CLL patients are analyzed using anti-CD44st moAbs. In these experiments, a molecular form of 82 kDa is immunoprecipitated from B-CLL cell lysates, in addition to
Quantitative determination of serum CD44st in the follow-up of B-CLL several bands displaying higher molecular weight. A similar immunoprecipitation pattern is also shown for sera from B-CLL patients and normal controls. However, the molecular Eighteen B-CLL patients were available for serial determination of serum CD44st in a time-period of 4-9 months.
weight of soluble CD44st is approximately 4 kDa lower in the serum than in cell lysates, 78 kDa vs 82 kDa, respectively Eleven patients were in stable disease as indicated by LDT Ͼ 1 year, absence of stage evolution and no need for therapy. Six (arrowhead and arrow in Figure 2a ). This indicates that soluble CD44 is presumably lacking the transmembrane portion and patients were treated after the first serum CD44st determination and were responding to therapy. One patient was the cytoplasmic tail of the molecule. When moAbs to CD44st were substituted by unrelated moAbs (eg anti-CD4), as the evaluated before and in the course of disease progression. Data in Table 3 show that no statistically significant changes primary reagent, no molecules similar to those recognized by anti-CD44st moAbs were detected (Figure 2a, lane 5) . The in CD44st occur in stable disease. In contrast, response to treatment is accompanied by a significant decrease of CD44st only bands consistently observed in these controls were of 30, 50 and 150 kDa, which correspond to the molecular mass serum levels. The patient with progressive disease unresponsive to conventional treatment (chlorambucil) showed a sigof Ig light and heavy chains, and of the complete mouse moAbs used in the assay. The same non-specific bands were nificant increase of CD44st serum levels (from 1220 ng/ml to also detected when anti-CD44st moAbs were used. As an matrix relationships, and are therefore central to the problem of tumor dissemination and metastasis. 51 Analysis of the additional control, we analyzed lysates from a lung adenocarcinoma cell line, A-549, that express CD44st but not its variadhesive phenotype of tumor cells may thus provide information on the clinical evolution of the disease. ant isoforms (our unpublished observations) (Figure 3 ). In comparison with B-CLL sera that show several immunopreci-
The proteoglycan CD44, originally described as the lymphocyte homing receptor, 52 is expressed on B-CLL cells. The pitation bands, only an 82 kDa band is observed in A-549 cell lysates.
existence of a CD44st form and of CD44v isoforms, particularly v5 and v6, that are associated with tumor progression To assess whether or not some of the high molecular weight bands corresponded to CD44 variant isoforms, sera from Band metastatic phenotype, provides the opportunity of extending the phenotypic characterization of the malignant CLL patients were immunoprecipitated using moAbs to CD44 v5 and v6 as primary reagents, followed by moAbs to CD44st. cells in order to define their capacity to circulate, extravasate and home into tissues. Both anti-variant antibodies demonstrate bands of molecular weight higher than 82 kDa (Figure 2b) . Bands with similar Expression of surface CD44st on B-CLL cells has allowed the distinction of two types of clones that express the receptor molecular weight were also present when anti-CD44st moAbs were used as the primary reagent (see Figure 2a) . at high or low density, in comparison with that of residual T cells. 47 This phenotypic feature is stable in time, is treatmentindependent and defines two groups of patients whose survival rate is significantly different. Patients with the CD44 high Discussion phenotype are longer survivors than those with the CD44 low phenotype. 48 Only a minority of B-CLL clones express v5 and B-CLL is a fairly benign lymphoproliferative disorder that is markedly heterogeneous both for phenotypic features of the v6 detectable by indirect immunofluorescence. However, in modulation experiments that yield patching of surface molmalignant cells and for disease course. A number of biological and clinical parameters are available that allow determination ecules, we have shown that CD44v5 and v6 can be detected on the surface of B-CLL cells in all cases, albeit at a very low of stage and predict evolution of B-CLL. [34] [35] [36] However, in many patients, the course of the disease based on currently density. 50 This is similar to that observed in activated T cells which express CD44v6 (and v9) at a density much lower (5-available criteria eludes prognostic evaluation. A search for novel disease indicators is thus justified. 10%) than that of CD44st. 53 Our observations in B-CLL are consistent with studies showing that in non-Hodgkin's lymAdhesion molecules have been extensively studied in neoplasia, since they regulate cell-to-cell and cell-to-extracellular phomas, cells from high-grade but not from low-grade malig- from the cell membrane and accumulates in serum and in other biological fluids. Shedding of CD44st occurs in the course of immune activation, inflammatory conditions and nancies express detectable CD44v6, [25] [26] [27] although this finding has not been confirmed in another study. 33 neoplasia.
28-31 Thus, it could be argued that in B-CLL, serum CD44st is elevated because it is released by cells other than Inasmuch as other adhesion molecules, CD44 sheds from the cell surface following interaction with ligand or ligation the malignant ones, eg residual normal T or NK cells, upon activation. We rule out this possibility because (1) serum by antibodies, and can therefore be detected in serum and other biological fluids. 54 Determinations of serum CD44st and CD44st levels correlate significantly with the number of circulating HL-DR + and sIg + B cells, a close reflection of tumor CD44v6 in solid tumors indicate that the amount of soluble molecules correlates with tumor burden and treatment burden (see Figure 1a) ; and (2) in B-CLL, a functional impairment has been described that leads to defective T cell response, thus providing a useful marker for disease monitoring. 32 This holds true also for Hodgkin's and non-Hodgkin's responses to antigens and mitogens. 55 It may thus be inferred that serum CD44st is released by neoplastic B cells. lymphomas. 33 Here we show that approximately 45% of B-CLL patients
The highly significant correlation between serum CD44st and ␤ 2 -microglobulin, a good indicator of tumor burden in Bhave above-normal CD44st serum levels which correlate significantly with a number of unfavorable prognostic features CLL, 42 further supports the usefulness of the novel tumor marker described in this study. In addition, CD44st represents such as high lymphocyte counts, splenomegaly, advanced disease stage and therapy requirement, but not LDT Ͻ12 months a valuable indicator of disease status because its serum levels vary according to the clinical behavior of the disease, as and diffuse bone marrow histology.
According to the available prognostic criteria (see Table 2 ), shown by our follow-up study (see Table 3 ). However, these data should be considered as preliminary, due to the relatively 46/122 patients were defined as smoldering B-CLL. [36] [37] [38] 40 However, in this low-risk group, 14/46 (30%) patients had low number of patients eligible for this follow-up study (18/122). elevated serum CD44st. Conversely, 40/76 (53%) high-risk patients had elevated serum CD44st. A long-term follow-up
As shown in other human and animal models, 28,31 soluble CD44st displays a molecular weight lower than that of the study will answer the questions raised by these findings, namely: are low risk patients with elevated serum CD44st cancellular form. In our immunoprecipitation experiments, the molecular weight is 82 kDa and 78 kDa for the cellular and didates for disease progression? Are high-risk patients with elevated serum CD44st poor responders to treatment and soluble form, respectively. In addition to the 80-90 kDa form, antibodies to CD44st immunoprecipitate, from both sera and short-term sruvivors? An answer to these questions should reinforce the value of serum CD44st as an independent progcell lysates, several heavier forms that may correspond to CD44v and/or to different degrees of glycosylation. These nostic indicator in B-CLL.
As is the case for other surface molecules, 54 CD44st sheds forms are specific because they are not detected in lysates of 
